


Fig. 2S

Fig. 2S. Diagram of adaptive phase I trial design; part 1 for dose escalation, and part 2 for dose optimization. Twenty-four patients with breast cancer were enrolled in part 1; There was no MDT dose observed in part 1. Part 2, Patients with advanced HCC (n=20); Breast cancer (n=1) and colorectal cancer (n=2), were enrolled and administrated with doses of icaritin 600 or 800 mg b.i.d .